Autolus Reports Strong AUCATZYL Revenue, Raises 2026 Guidance, Extends Cash Runway, and Advances Pipeline

summarizeSummary

Autolus Therapeutics announced strong preliminary 2025 AUCATZYL revenue and robust 2026 guidance, alongside significant pipeline advancements and an extended cash runway into Q4 2027.

check_boxKey Events

• Strong 2025 Revenue & 2026 Guidance

  Reported preliminary unaudited AUCATZYL net product revenue of approximately $75 million for full year 2025, with 2026 guidance projected at $120 million to $135 million.

• Extended Cash Runway

  Company expects current cash, cash equivalents, and marketable securities to fund operations into the fourth quarter of 2027.

• Pipeline Advancements

  Advancing obe-cel into Phase 2 for pediatric r/r B-ALL and lupus nephritis (LUMINA trial now enrolling), with FDA alignment on a potential registrational path for LN. Initiated Phase 1 trials for progressive multiple sclerosis (BOBCAT) and light-chain amyloidosis (ALARIC).

• Anticipated Gross Margin Improvement

  Expects a shift from negative to positive gross margin in 2026 due to increasing patient numbers and operational efficiencies in manufacturing.

auto_awesomeAnalysis

Autolus Therapeutics announced robust preliminary 2025 revenue for its lead product, AUCATZYL, and provided strong 2026 guidance, signaling significant commercial traction. The extension of the cash runway into Q4 2027 substantially de-risks the company's financial position, reducing immediate capital concerns. Furthermore, the advancement of multiple pipeline programs, including obe-cel into Phase 2 for pediatric B-ALL and lupus nephritis with FDA alignment on a potential registrational path, underscores the broad potential of its CAR T cell therapy platform. The anticipated shift to positive gross margins in 2026 also indicates improving operational efficiency and a clearer path to profitability.